

ARTICLE OPEN

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a *post hoc* analysis of the TIOSPIR trialRobert Wise¹, Peter MA Calverley², Ronald Dahl³, Daniel Dusser⁴, Norbert Metzdorf⁵, Achim Müller⁶, Andy Fowler⁷ and Antonio Anzueto⁸

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) who were naive to anticholinergics before the TIOtropium Safety and Performance In Respimat (TIOSPIR) trial may reflect patients seen in practice, in particular in primary care. In addition, investigating safety in these patients avoids the potential bias in patients who previously received anticholinergics and may be tolerant of their effects.

AIMS: The aim of this study was to evaluate whether patients naive to anticholinergic therapy who were treated with tiotropium Respimat 2.5 or 5 µg had different safety and efficacy outcomes than patients treated with tiotropium HandiHaler 18 µg.

METHODS: A *post hoc* analysis of patients who were not receiving anticholinergics before TIOSPIR ($N=6,966/17,135$) was conducted. Primary end points were risk of death from any cause and risk of COPD exacerbation. Secondary outcomes included severe exacerbation and major adverse cardiovascular events (MACE). Additional analysis of exacerbations was carried out in anticholinergic-naive patients with moderate (GOLD II) disease.

RESULTS: Anticholinergic-naive patients had less severe disease than the total TIOSPIR population. Discontinuations because of anticholinergic side effects were infrequent (0.9% overall). Similar to the primary study, patients in the tiotropium Respimat groups had no difference in the risk of death or risk of any or severe exacerbation than patients treated with tiotropium HandiHaler. Risk of MACE was similar across the Respimat and HandiHaler groups. Rates of exacerbations in the subgroup of patients with moderate disease were similar across the Respimat and HandiHaler groups.

CONCLUSIONS: Tiotropium Respimat and HandiHaler have similar safety and efficacy profiles in patients who are naive to anticholinergic therapy.

npj Primary Care Respiratory Medicine (2015) 25, 15067; doi:10.1038/npjpcrm.2015.67; published online 5 November 2015

INTRODUCTION

Tiotropium (SPIRIVA, Boehringer Ingelheim Pharma & Co KG, Ingelheim am Rhein, Germany) is a once-daily, long-acting, anticholinergic bronchodilator available in two formulations: dry powder via HandiHaler (18 µg once daily) and as an aqueous solution via the Respimat Soft Mist Inhaler (5 µg (two puffs of 2.5 µg once daily)).^{1,2} Tiotropium HandiHaler 18 µg and tiotropium Respimat 5 µg have demonstrated similar improvements in lung function, symptoms and quality of life^{3–6} and have similar pharmacokinetic profiles in patients with chronic obstructive pulmonary disease (COPD).⁷

Queries around the safety of Respimat^{8–10} were addressed in the TIOtropium Safety and Performance In Respimat (TIOSPIR; NCT01126437) trial¹¹—the largest long-term, randomised, double-blind trial in patients with COPD performed to date. The trial showed similar safety and exacerbation efficacy profiles for tiotropium Respimat 2.5 µg and 5 µg compared with HandiHaler 18 µg.

A common criticism of randomised clinical trials (RCTs) is that the selected patient populations may not be truly representative

of patients seen in routine clinical practice—in particular, patients treated in primary care.^{12–14} A unique characteristic of TIOSPIR was the liberal inclusion criteria that were chosen to select a typical COPD patient population, including patients with a wide range of disease severities, as well as patients with stable cardiac disease.¹¹

TIOSPIR also included a large population of patients with COPD who were naive to anticholinergic treatment at baseline. This represents an important patient group that may be highly representative of patients commonly seen in primary care. Patients within the primary TIOSPIR study who were previously treated with anticholinergics might be seen to constitute a selected population with a higher tolerance to anticholinergic effects and could have introduced a selection bias in the analysis of tiotropium's safety. Therefore, it is conceivable that the anticholinergic-naive group might have been at an increased risk of side effects commonly associated with the class and may have responded differently to treatment with tiotropium Respimat or HandiHaler.

To investigate this possibility, this *post hoc* analysis of the TIOSPIR trial studied whether patients who had not previously

¹Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; ²Respiratory Medicine, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK; ³Allergy Centre, Odense University Hospital, Odense C, Denmark; ⁴Service de Pneumologie, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; ⁵Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; ⁶Global Clinical Operations, Biometry and Data Management, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; ⁷Medical Affairs, Boehringer Ingelheim Pharma Ltd, Bracknell, UK and ⁸Department of Medicine, Pulmonary Critical Care Center, University of Texas Health Science Center, San Antonio, TX, USA.

Correspondence: R Wise (rwise@jhmi.edu)

Received 2 April 2015; revised 14 August 2015; accepted 15 September 2015

received anticholinergic therapy and who were treated with Respimat 2.5 or 5 µg had different safety and/or efficacy outcomes compared with patients treated with HandiHaler 18 µg.

MATERIALS AND METHODS

Study design

TIOSPIR was a large ($N=17,135$) long-term (2–3 years), randomised, double-blind, double-dummy, parallel-group, actively controlled, event-driven trial in patients with COPD.^{11,15} Patients received once-daily Respimat 2.5 µg (two puffs of 1.25 µg) or 5 µg (two puffs of 2.5 µg) or once-daily HandiHaler 18 µg. Primary outcomes were time to death from any cause and time to first COPD exacerbation. Secondary outcomes included time to severe (hospitalised) exacerbations and time to major adverse cardiovascular events (MACE). The study design has been described previously.^{11,15}

Study population

Patients had a diagnosis of COPD with forced expiratory volume in 1 s (FEV_1) $\leq 70\%$ of forced vital capacity, $FEV_1 \leq 70\%$ predicted and ≥ 10 pack-years of smoking history, were aged ≥ 40 years and were permitted to use their usual background treatment for COPD other than anticholinergics. All patients (including those with premature discontinuation) were followed up for vital status until the end of the study.

At enrolment, patients were asked to provide details of COPD and other medication received within the past 2 months. For this *post hoc* subgroup analysis, patients were included if they were not receiving short- or long-acting inhaled anticholinergics during the 2 months before the start of the trial.

Statistical analysis

Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using a Cox-proportional hazards regression model (without covariate adjustment). Rate ratios and 95% CI were used to compare incidence rates. Negative binomial regression models were used to compare event rates.

For analysis of death (including fatal MACE), events occurring during treatment and vital status follow-up (vital status analysis) were considered. For all other analyses (including MACE and COPD exacerbations), only events with onset in the on-treatment period were noted (on-treatment analysis). An on-treatment sensitivity analysis was conducted for time to death. Subgroup analyses by patient characteristics at baseline were conducted for time to death and exacerbation risk.

RESULTS

Study population

Overall, 6,966 patients naive to anticholinergic treatment at baseline (Respimat 2.5 µg $n=2,345$; Respimat 5 µg $n=2,312$; HandiHaler 18 µg $n=2,309$) were randomised and treated for a mean follow-up duration of 834 days. A total of 541 (23.1%), 517 (22.4%) and 500 (21.7%) patients in the Respimat 2.5 µg, 5 µg and HandiHaler 18 µg groups, respectively, prematurely discontinued from the study. Discontinuation attributed to anticholinergic side effects occurred in 0.7 and 1.0% of patients in the Respimat 2.5 and 5 µg groups, respectively, and 0.9% of patients in the HandiHaler group.

Patient baseline demographics and characteristics were similar in the three groups (Table 1). Most patients were Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages II (48.8%) and III (38.4%). The majority of patients (77.3%) were receiving pulmonary medication at baseline; approximately half of the patients were taking an inhaled corticosteroid or long-acting β_2 -agonist (50.2 and 51.6%, respectively) (Table 1). Of the patients who reported symptoms of breathlessness ($n=6,688$; 96.1%), the majority were classified as modified Medical Research Council (mMRC) scale 1 ($n=2,694$, 40.3%) or scale 2 ($n=2,486$, 37.2%) (Table 1). Approximately 8–9% of patients had a history of cardiac arrhythmia (Table 1). A total of 3,349 (48.1%) patients had ≥ 1 COPD exacerbation in the year before the study (Table 1).

Table 1. Patient disposition and baseline characteristics in anticholinergic-naive patients

Variable	Tiotropium Respimat 2.5 µg (n = 2,344)	Tiotropium Respimat 5 µg (n = 2,309)	Tiotropium HandiHaler 18 µg (n = 2,307)
Gender, n (%)			
Male	1,686 (71.9)	1,694 (73.4)	1,641 (71.1)
Mean age, years (s.d.)	64.1 (9.3)	64.0 (9.2)	64.1 (9.2)
BMI, mean kg/m ² (s.d.)	26.1 (5.7)	26.0 (5.7)	26.1 (5.8)
Smoking history, mean pack-years (s.d.)	42.2 (24.3)	42.5 (23.9)	41.6 (23.6)
Post-bronchodilator spirometry, mean (s.d.)			
FEV ₁ , L	1.365 (0.495)	1.374 (0.494)	1.360 (0.488)
FEV ₁ , % predicted	48.7 (14.1)	48.8 (13.9)	48.8 (14.2)
FVC, L	2.688 (0.835)	2.711 (0.840)	2.685 (0.846)
Ratio of FEV ₁ to FVC	0.512 (0.116)	0.511 (0.114)	0.511 (0.113)
GOLD stage, n (%)			
I	4 (0.2)	10 (0.4)	7 (0.3)
II	1,142 (48.7)	1,112 (48.2)	1,140 (49.4)
III	896 (38.2)	908 (39.3)	868 (37.6)
IV	261 (11.1)	238 (10.3)	263 (11.4)
mMRC score, n (%)			
0 (including not breathless)	186 (8.0)	200 (8.7)	216 (9.4)
1	923 (39.5)	871 (37.8)	900 (39.1)
2	841 (36.0)	832 (36.1)	813 (35.3)
3	350 (15.0)	370 (16.1)	331 (14.4)
4	38 (1.6)	32 (1.4)	42 (1.8)
Patients with exacerbations in the previous year, n (%)			
0	1,210 (51.6)	1,203 (52.1)	1,191 (51.6)
1	654 (27.9)	653 (28.3)	666 (28.9)
≥ 2	477 (20.3)	451 (19.5)	448 (19.4)
Previous cardiac arrhythmia, n (%)	208 (8.9)	212 (9.2)	194 (8.4)
Previous MI, n (%)	118 (5.0)	122 (5.3)	117 (5.1)
Previous stroke, n (%)	53 (2.3)	56 (2.4)	46 (2.0)
Previous IHD or CAD, n (%)	346 (14.8)	334 (14.5)	333 (14.4)
Taking CV medication, n (%)	1,109 (47.3)	1,062 (46.0)	1,061 (46.0)
Use of respiratory medication, n (%)	1,830 (78.1)	1,764 (76.4)	1,785 (77.4)
LABA	1,195 (51.0)	1,177 (51.0)	1,219 (52.8)
SABA	1,076 (45.9)	1,061 (46.0)	1,052 (45.6)
ICS	1,167 (49.8)	1,152 (49.9)	1,175 (50.9)

Abbreviations: BMI, body mass index; CAD, coronary artery disease; CV, cardiovascular; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; IHD, ischaemic heart disease; LABA, long-acting β_2 -agonist; MI, myocardial infarction; mMRC, modified Medical Research Council; SABA, short-acting β_2 -agonist; s.d., standard deviation.

Six patients (Respimat 2.5 µg, one patient; Respimat 5 µg, three patients; HandiHaler 18 µg, two patients) from sites with data irregularities were excluded.

Safety

Risks of death (measured as time to death, vital status analysis) and the adjudicated causes of death were similar between both doses of Respimat and HandiHaler 18 µg (Figures 1a, b; Table 2). Similar results were obtained for an on-treatment sensitivity analysis of time to fatal adverse event (Respimat 2.5 µg versus Respimat 5.0 µg: HR (95% CI) 1.21 (0.95, 1.54); Respimat 2.5 µg versus HandiHaler 18 µg: HR (95% CI) 1.11 (0.87, 1.40); Respimat 5 µg versus HandiHaler 18 µg: 0.91 (0.71, 1.17)). Subgroup analyses (including cardiac history at baseline and pulmonary comedication at baseline) showed no difference between groups.

Risk of first MACE (on-treatment analysis) was similar for Respimat 2.5 µg and 5.0 µg versus HandiHaler 18 µg (HR (95% CI): 1.11 (0.81, 1.51) $P=0.523$, and HR (95% CI) 1.20 (0.88, 1.63) $P=0.244$,




Figure 1. Kaplan–Meier plots showing time to (a) death, (b) FAE, (c) first MACE and (d) fatal MACE. Data for patients with event are *n* (%). CI, confidence interval; COPD, chronic obstructive pulmonary disease; FAE, fatal adverse event; MACE, major adverse cardiovascular event. Six patients (Respimat 2.5 µg, one patient; Respimat 5 µg, three patients; HandiHaler 18 µg, two patients) from sites with data irregularities were excluded from first MACE analyses. On-treatment analyses (from randomisation to drug stop+30 days).

respectively; Figure 1c). Rates of fatal MACE (vital status analysis) were similar in each of the treatment groups (Figure 1d; Table 2).

Efficacy

Risk of exacerbation (measured as time to first exacerbation, on-treatment analysis) showed no significant difference

between the Respimat groups and HandiHaler 18 µg (Figure 2a; Table 3). The risk of moderate-to-severe and severe (hospitalised) exacerbations was also similar across groups (Figure 2b; Table 3).

Exacerbation risk did not differ between treatments in any of the patient subgroups. Patients with less impaired lung function

Table 2. Incidence of adjudicated causes of mortality and fatal MACE in anticholinergic-naive patients

Variable	Tiotropium Respimat 2.5 µg (n = 2,345)	Tiotropium Respimat 5 µg (n = 2,312)	Tiotropium HandiHaler 18 µg (n = 2,309)	Rate ratio (95% CI)	
				Tiotropium Respimat 2.5 µg vs. HandiHaler	Tiotropium Respimat 5 µg vs. HandiHaler
Total patients with deaths	169 (3.2)	149 (2.8)	159 (3.0)	1.05 (0.84, 1.30)	0.93 (0.75, 1.17)
Patients with fatal MACE	49 (0.9)	49 (0.9)	43 (0.8)	1.12 (0.75, 1.69)	1.14 (0.75, 1.71)
<i>Adjudicated causes of death</i>					
Cardiac disorders	10 (0.2)	13 (0.2)	5 (0.1)	1.97 (0.67, 5.77)	2.59 (0.92, 7.27)
General disorders including sudden (cardiac) death	53 (1.0)	41 (0.8)	46 (0.9)	1.14 (0.77, 1.69)	0.89 (0.58, 1.35)
Neoplasms benign, malignant and unspecified	44 (0.8)	29 (0.5)	32 (0.6)	1.36 (0.86, 2.14)	0.90 (0.55, 1.49)
Respiratory, thoracic and mediastinal disorders	36 (0.7)	34 (0.6)	36 (0.7)	0.99 (0.62, 1.57)	0.94 (0.59, 1.50)
COPD (PT)	34 (0.6)	31 (0.6)	34 (0.6)	0.99 (0.61, 1.59)	0.91 (0.56, 1.48)
Infections and infestations	10 (0.2)	10 (0.2)	13 (0.2)	0.76 (0.33, 1.73)	0.77 (0.34, 1.75)
Gastrointestinal disorders	3 (0.1)	9 (0.2)	8 (0.2)	0.37 (0.10, 1.39)	1.12 (0.43, 2.91)

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; MACE, major adverse cardiovascular event; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; SOC, system organ class. Data shown are *n* (rate per 100 patient-years). Risk-adjusted rates of adjudicated causes of death by treatment, MedDRA (version 16.0, MedDRA MSSO, McLean, VA, USA) SOC and PT. Vital status analysis. MACE included stroke, myocardial infarction, sudden death, cardiac death, sudden cardiac death or fatal event in the SOCs for cardiac and vascular disorders.




Figure 2. Kaplan–Meier plots showing time to (a) first exacerbation, and (b) first severe (hospitalised) exacerbation. Data for patients with event are *n* (%). COPD exacerbations were defined as the worsening of two or more major respiratory symptoms (dyspnoea, cough, sputum, chest tightness or wheezing) with a duration of at least 3 days requiring specified treatment changes: (a) mild exacerbations: a newly prescribed maintenance bronchodilator; (b) moderate exacerbations: a prescription for antibiotics, systemic glucocorticoids or both; (c) severe exacerbations: hospitalisation. Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease. Six patients (Respimat 2.5 µg, one patient; Respimat 5 µg, three patients; HandiHaler 18 µg, two patients) from sites with data irregularities were excluded from analyses. On-treatment analyses (from randomisation to drug stop+1 day).

(GOLD stage II) responded equally to Respimat and HandiHaler with respect to the rate of any exacerbation, moderate-to-severe exacerbations and severe exacerbations (Table 3). As might be expected, patients in the GOLD stage II category experienced fewer exacerbations than the overall population of anticholinergic-naive patients (Table 3).

DISCUSSION

Main findings

The present study showed that patients with COPD who were naive to anticholinergic treatment at baseline, and who were treated with Respimat 2.5 or 5 µg, were at a similar risk of mortality and adverse cardiac events as patients receiving HandiHaler 18 µg.

Table 3. Risk of exacerbation in anticholinergic-naive patients

Variable	Tiotropium Respimat 2.5 µg (n = 2,344)	Tiotropium Respimat 5 µg (n = 2,309)	Tiotropium HandiHaler 18 µg (n = 2,307)	Hazard ratio (95% CI); P-value	
				Tiotropium Respimat 2.5 µg versus HandiHaler	Tiotropium Respimat 5 µg versus HandiHaler
<i>All patients</i>					
Any exacerbation					
Patients with event, n (%)	979 (41.8)	923 (40.0)	948 (41.1)	1.04 (0.95, 1.14); P = 0.359	0.99 (0.90, 1.08); P = 0.829
No. of events	2,022	2,002	1,955		
Adjusted rate of events/patient-year (95% CI)	0.45 (0.42, 0.48)	0.45 (0.42, 0.48)	0.44 (0.41, 0.47)		
Moderate-to-severe exacerbation					
Patients with event, n (%)	957 (40.8)	902 (39.1)	926 (40.1)	1.04 (0.95, 1.14); P = 0.364	0.99 (0.90, 1.09); P = 0.840
No. of events	1,968	1,956	1,902		
Adjusted rate of events/patient-year (95% CI)	0.43 (0.40, 0.47)	0.44 (0.41, 0.47)	0.43 (0.40, 0.46)		
Severe (hospitalised) exacerbations					
Patients with event, n (%)	282 (12.0)	250 (10.8)	255 (11.1)	1.10 (0.93, 1.30); P = 0.277	0.99 (0.83, 1.18); P = 0.917
No. of events	406	376	363		
Adjusted rate of events/patient-year (95% CI)	0.09 (0.08, 0.11)	0.09 (0.08, 0.10)	0.08 (0.07, 0.10)		
<i>GOLD stage II subgroup</i>					
Any exacerbation					
Patients with event, n (%)	442 (38.6)	391 (34.8)	426 (37.1)	1.05 (0.92, 1.20); P = 0.472	0.95 (0.82, 1.08); P = 0.422
No. of events	851	809	837		
Adjusted rate of events/patient-year (95% CI)	0.38 (0.34, 0.42)	0.37 (0.34, 0.42)	0.38 (0.34, 0.42)		
Moderate-to-severe exacerbation					
Patients with event, n (%)	428 (37.3)	380 (33.9)	415 (36.2)	1.04 (0.91, 1.19); P = 0.546	0.94 (0.82, 1.08); P = 0.410
No. of events	822	781	817		
Adjusted rate of events/patient-year (95% CI)	0.36 (0.33, 0.40)	0.36 (0.32, 0.40)	0.37 (0.33, 0.41)		
Severe (hospitalised) exacerbations					
Patients with event, n (%)	84 (7.3)	61 (5.4)	78 (6.8)	1.07 (0.79, 1.46); P = 0.650	0.81 (0.58, 1.13); P = 0.206
No. of events	116	84	113		
Adjusted rate of events/patient-year (95% CI)	0.05 (0.04, 0.07)	0.04 (0.03, 0.05)	0.05 (0.04, 0.07)		

Abbreviations: CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

On-treatment analysis (from randomisation to drug stop+1 day). Six patients (Respimat 2.5 µg, one patient; Respimat 5 µg, three patients; HandiHaler 18 µg, two patients) from sites with data irregularities were excluded.

Compared with the overall population, the present patient subgroup was similar to the TIOSPIR primary study population with regards to baseline characteristics; however, mortality rates during the study were slightly lower. It is likely that patients who were anticholinergic naive at baseline had less severe disease than the overall population; indeed, a slightly higher percentage of patients was classified as GOLD stage II. In addition, patients in the anticholinergic-naive subgroup were receiving fewer cardiovascular medications at baseline, indicating fewer cardiovascular comorbidities. Together, this may have contributed to the lower mortality rates observed. Nevertheless, the results of this *post hoc* analysis of TIOSPIR were consistent with the main study findings. In addition, the analysis addresses concerns that the safety of tiotropium Respimat could not be completely demonstrated in TIOSPIR because of a potentially selected population with a higher tolerance to anticholinergic effects at baseline.

Interpretation of findings in relation to previously published work COPD is a heterogeneous disease comprising a wide range of clinical phenotypes that may respond differently to treatment.¹⁶ Not all of these phenotypes (particularly patients with mild COPD) are represented within populations included in RCTs. Indeed, a common criticism of evidence-based medicine is that it is not known how well RCT evidence applies to COPD patients typically seen within clinical practice.^{12–14}

In a comparison of primary care data from the Uncovering and Noting Long-term Outcomes in COPD (UNLOCK) database with six large RCTs of patients with COPD, significant differences were observed with respect to baseline characteristics.¹³ Patients included in the RCTs tended to be younger, were predominantly male and had significantly worse lung function and quality-of-life scores than primary care patients. Disparities were also observed with respect to exacerbations: a lower mean exacerbation rate per year and lower number of patients with ≥ 1 or ≥ 2 exacerbations

being observed in the UNLOCK population.¹³ A further interesting observation from the UNLOCK analysis is that patients with GOLD stage I or II COPD comprised 20.7% and 53.3%, respectively, of the total UNLOCK population.¹³ This compares with a complete absence of patients at GOLD stage I and 45% of patients at GOLD stage II in the combined RCTs, normally caused by exclusion criteria for mild patients. In the TIOSPIR anticholinergic-naïve subpopulation, 0.3% patients were at GOLD stage I (because of the inclusion of patients with an FEV₁ percent predicted of < 70%) and 48.8% patients were at GOLD stage II. Thus, almost half of the patients in this subgroup were considered to have moderate COPD. Comparison of other baseline characteristics from the TIOSPIR anticholinergic-naïve subpopulation with those from the UNLOCK cohort and combined RCTs indicate that this subgroup may have greater similarity to the UNLOCK population than other large COPD trials. Fewer patients in the anticholinergic subgroup had also experienced one or more exacerbation in the year before the study (48%) than patients from other large RCTs (59%), thus better reflecting the UNLOCK population (44%; Supplementary Table 1). Together, these comparisons indicate that the anticholinergic-naïve subgroup from TIOSPIR may better reflect patients observed in primary care than patients typically randomised to other large COPD trials.

The primary efficacy outcome from TIOSPIR was time to first COPD exacerbation. Exacerbations are an important component of COPD, having a significant impact on disease progression and health status, as well as increasing the risk of further exacerbations and death.^{17–19} Thus, the prevention of exacerbations is a primary goal in COPD management.²⁰ Tiotropium Respimat and HandiHaler have been shown to reduce COPD exacerbations versus placebo and other therapies, including among subgroups of patients.^{6,21–28} For example, in a prespecified secondary analysis of the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial, tiotropium HandiHaler reduced the number of exacerbations per patient-year by 16% versus control in patients naïve to maintenance therapy before the study.²⁵ In subgroup analyses of the Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) study, tiotropium HandiHaler significantly prolonged the time to first exacerbation (HR (95% CI), 0.88 (0.79, 0.99); $P=0.028$) and first severe exacerbation (HR (95% CI), 0.66 (0.48, 0.91); $P=0.012$) in GOLD stage II patients, and significantly reduced the annual exacerbation rate (rate ratio [95% CI], 0.77 (0.63, 0.94); $P=0.012$) in maintenance therapy-naïve patients, when compared with salmeterol.²⁷ Before TIOSPIR, the relative efficacy of exacerbation reduction by Respimat and HandiHaler was unknown. In this current *post hoc* analysis, the incidence of exacerbations was shown to be similar among anticholinergic-naïve patients who were treated with either Respimat or HandiHaler. Furthermore, the subgroup analysis of exacerbation risk in GOLD stage II patients shows that Respimat and HandiHaler have similar efficacy profiles in patients with less impaired lung function or health status.

Further evidence for tiotropium's safety was provided by the low incidence of discontinuations observed in each of the treatment groups because of anticholinergic side effects. Other clinical studies of tiotropium in COPD have reported similarly low rates of discontinuation because of undesirable effects such as dry mouth, occurring in 0.1% of patients treated with tiotropium Respimat 5 µg (5 clinical trials)² and 0.2% of patients treated with tiotropium HandiHaler 18 µg (28 clinical trials).¹

Strengths and limitations of this study

A key limitation of the study is that it was a *post hoc* analysis rather than a prespecified subgroup analysis. Nevertheless, being one of the largest, long-term, randomised trials of a broad range of patients with COPD, TIOSPIR lends itself to statistically powerful subgroup analyses.

Implications for future research, policy and practice

This *post hoc* analysis examined whether the subpopulation of patients in TIOSPIR who were naïve to anticholinergic therapy at baseline responded differently to treatment with tiotropium Respimat than to tiotropium HandiHaler. Patients who are naïve to anticholinergic therapy are frequently seen within daily practice, and the results of this analysis will therefore be of particular interest to primary care physicians and policy makers. Better definition of treatment responses of individuals according to their treatment history will ultimately help tailor more targeted interventions in patients with COPD.

Conclusions

In this *post hoc* analysis, patients with COPD who were naïve to anticholinergic treatment had similar efficacy and safety profiles when treated with tiotropium Respimat or HandiHaler in the TIOSPIR trial.

This study provides further data that addresses prior safety concerns regarding tiotropium Respimat and provides additional evidence that tiotropium Respimat treatment is also safe for patients who were not previously treated with an anticholinergic, including patients with mild disease more commonly seen in primary care.

ACKNOWLEDGEMENTS

Editorial and writing assistance was provided by Carol A Richter and Sarah J Petit at PAREXEL (funded by Boehringer Ingelheim). The TIOSPIR trial and this subsequent *post hoc* analysis were funded by Boehringer Ingelheim.

CONTRIBUTIONS

Writing assistance was provided by PAREXEL, and all authors had equal contribution in terms of reviewing all drafts. All authors had full access to the data and read and approved the final manuscript.

COMPETING INTERESTS

RW reports receiving consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Mylan, Novartis, Pfizer, Pulmonx, Roche, Spiration and Sunovion, with grant support from Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, Takeda and Pearl Therapeutics; PMAC reports receiving consulting fees, lecture fees and travel support from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Takeda; RD reports receiving consulting fees, lecture fees and grant support from Boehringer Ingelheim and Novartis; DD reports receiving consulting fees, lecture fees and payment for the development of educational activities from Boehringer Ingelheim, Chiesi, Dey Pharma, Novartis, Nycomed and Pfizer; AA reports receiving consulting fees, lecture fees and travel support from AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline and Novartis, and grant support to the University of Texas Health Science Centre from GlaxoSmithKline; NM, AF and AM are employees of Boehringer Ingelheim.

FUNDING

Funding was provided by Boehringer Ingelheim.

REFERENCES

- Boehringer Ingelheim: *Summary of Product Characteristics (SPC): Spiriva 18 microgram inhalation powder, hard capsule*. EMC. Boehringer Ingelheim Ltd. February 2015. Available at: <https://www.medicines.org.uk/emc/medicine/10039>.
- Boehringer Ingelheim: *Summary of Product Characteristics (SPC): Spiriva Respimat 2.5 microgram, inhalation solution*. EMC. Boehringer Ingelheim Ltd. January 2015. Available at: <https://www.medicines.org.uk/emc/medicine/201341>
- Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2014; **7**: CD009285.
- Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. *Drugs* 2012; **72**: 273–300.

- 5 Keating GM. Tiotropium Respimat® Soft Mist inhaler: a review of its use in chronic obstructive pulmonary disease. *Drugs* 2014; **74**: 1801–1816.
- 6 Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S *et al*. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med* 2008; **359**: 1543–1554.
- 7 Hohlfeld JM, Sharma A, van Noord JA, Cornelissen PJ, Derom E, Towse L *et al*. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. *J Clin Pharmacol* 2014; **54**: 405–414.
- 8 Boehringer Ingelheim: Tiotropium (Spiriva) Respimat: evaluation of fatal events. Boehringer Ingelheim Ltd. 2010. Available at: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/Pooled%20analysis/PA_205.372_251_252_254_255_U10-3255-01.pdf
- 9 Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. *Thorax* 2013; **68**: 48–56.
- 10 Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. *BMJ* 2011; **342**: d3215.
- 11 Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B *et al*. Tiotropium Respimat inhaler and the risk of death in COPD. *N Engl J Med* 2013; **369**: 1491–1501.
- 12 Herland K, Akselsen JP, Skjonsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? *Respir Med* 2005; **99**: 11–19.
- 13 Kruijs AL, Stallberg B, Jones RC, Tsiligianni IG, Lisspers K, van der Molen T *et al*. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. *PLoS ONE* 2014; **9**: e90145.
- 14 Travers J, Marsh S, Caldwell B, Williams M, Aldington S, Weatherall M *et al*. External validity of randomized controlled trials in COPD. *Respir Med* 2007; **101**: 1313–1320.
- 15 Wise RA, Anzueto A, Calverley P, Dahl R, Dusser D, Pledger G *et al*. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. *Respir Res* 2013; **14**: 40.
- 16 Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. *Chest* 2002; **121**(5 Suppl): 121S–126S.
- 17 Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. *Eur Respir J* 2007; **29**: 1224–1238.
- 18 Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. *Thorax* 2002; **57**: 847–852.
- 19 Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax* 2005; **60**: 925–931.
- 20 Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of COPD. Available at: <http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html>, 2015.
- 21 Bateman ED, Tashkin D, Siafakas N, Dahl R, Towse L, Massey D *et al*. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. *Respir Med* 2010; **104**: 1460–1472.
- 22 Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G *et al*. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. *Lancet Respir Med* 2014; **2**: 472–486.
- 23 Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C *et al*. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. *Lancet Respir Med* 2013; **1**: 524–533.
- 24 Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L *et al*. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. *Ann Intern Med* 2005; **143**: 317–326.
- 25 Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP *et al*. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. *Eur Respir J* 2010; **36**: 65–73.
- 26 Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM *et al*. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. *N Engl J Med* 2011; **364**: 1093–1103.
- 27 Vogelmeier C, Fabbri LM, Rabe KF, Beeh KM, Schmidt H, Metzendorf N *et al*. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naive patients. *Respir Med* 2013; **107**: 75–83.
- 28 Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF *et al*. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. *Lancet Respir Med* 2013; **1**: 199–209.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Supplementary Information accompanies the paper on the *npj Primary Care Respiratory Medicine* website (<http://www.nature.com/npjpcrm>)